• SM-102 in mRNA Delivery: Protocol Innovations and Troublesho

  2026-06-25

  SM-102, or heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate, sets a new standard for mRNA delivery in lipid nanoparticle (LNP) systems. This article decodes the latest experimental workflows, protocol enhancements, and troubleshooting strategies, using recent bladder cancer mRNA therapy as a practical showcase.

• β-Amanitin in RNA Polymerase II Transcription Studies: Proto

  2026-06-24

  β-Amanitin is the gold-standard tool for dissecting RNA polymerase II function and mRNA synthesis inhibition in eukaryotic cells. This article translates recent computational and immunodetection breakthroughs into actionable workflows, troubleshooting advice, and comparative insights for transcriptional regulation research and toxicology applications.

• EdU Flow Cytometry Assay Kits (Cy3): Precision in Cell Proli

  2026-06-23

  EdU Flow Cytometry Assay Kits (Cy3) enable sensitive, non-denaturing measurement of DNA synthesis during cell proliferation. These kits leverage click chemistry for efficient S-phase detection, offering clear advantages over traditional BrdU assays. Their robust performance is validated in cancer research and genotoxicity testing workflows.

• Chloroquine in Research: Protocols, Applications, and Troubl

  2026-06-23

  Chloroquine’s unique inhibition of autophagy and immune signaling makes it an indispensable research tool for malaria, autoimmune, and cancer studies. This article delivers actionable workflow strategies, protocol parameters, and troubleshooting insights to optimize your experiments with APExBIO’s high-purity Chloroquine.

• Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI

  2026-06-22

  This study introduces a mannose-modified lipid nanoparticle system for targeted delivery of human erythropoietin mRNA to inflammatory macrophages in spinal cord injury. The approach enables localized EPO expression, suppresses ferroptosis, and enhances neuroprotection, representing a significant translational advance for mRNA-based neurorepair.

• Applied Strategies with Doxorubicin Hydrochloride in Cancer

  2026-06-22

  Doxorubicin hydrochloride (Adriamycin HCl) is central to oncology and cardiotoxicity research, yet workflow optimization and accurate drug encapsulation remain critical hurdles. This article decodes advanced experimental strategies, best-in-class encapsulation efficiency assessment, and actionable troubleshooting tips—empowering researchers to maximize both scientific rigor and translational relevance.

• Functional Genomic Screens Reveal Drug-Induced Death Mechani

  2026-06-21

  Honeywell et al. introduce MEDUSA, a simulation-assisted analytic strategy that disentangles growth and death rate contributions in pooled functional genomic screens. This innovation clarifies the genetic determinants of drug sensitivity and cell death, offering researchers a more precise means to interpret high-throughput chemo-genetic data and guide targeted therapeutic studies.

• Sumatriptan as an Anti-Inflammatory: Evidence Beyond Migrain

  2026-06-20

  This systematic review systematically evaluates the anti-inflammatory actions of sumatriptan, a 5-HT1B/1D receptor agonist long used for migraine. Key findings reveal that sumatriptan modulates cytokine release and nitric oxide pathways, suggesting repositioning opportunities for inflammatory conditions.

• RG7388: Advancing MDM2 Antagonist Strategies for Synergistic

  2026-06-19

  Explore how RG7388, a potent MDM2 antagonist, enables advanced strategies for p53 pathway activation and synergistic cancer therapy. This article uniquely bridges mechanistic insights with practical assay and combination protocol guidance.

• Rotavirus Infection Disrupts Nrf2-Driven Redox Defense Pathw

  2026-06-19

  This study demonstrates that progressive rotavirus infection leads to marked downregulation of the redox-sensitive transcription factor Nrf2 and its target genes, despite initial induction during early oxidative stress. The findings clarify mechanisms of viral interference with cellular antioxidant defenses and highlight the complexity of Nrf2 regulation during infection, with implications for antiviral research and therapeutic targeting.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Mechan

  2026-06-18

  This article critically reviews recent evidence for intravesical delivery of p21 mRNA–loaded lipid nanoparticles as a tumor suppressor replacement therapy in non–muscle-invasive bladder cancer. The study establishes a mechanistically grounded, localized mRNA therapy approach that suppresses tumor growth and restores p21 expression, with practical implications for translational oncology.

• Thymoquinone in Cardiotoxicity: Mechanisms and Translational

  2026-06-18

  This article explores thymoquinone's mechanistic role as a small-molecule probe in the mitigation of doxorubicin-induced cardiotoxicity, outlining key experimental insights, protocol guidance, and its broader translational implications. With a focus on advanced pathway modulation—including VEGFR2–PI3K–Akt axis inhibition, STAT3 suppression, and anti-ferroptotic effects—this thought leadership piece provides strategic direction for researchers pushing the boundaries of cardioprotection and oxidative stress modeling.

• DEGS2 Drives Prostate Cancer Stemness via PI3K-AKT and Phyto

  2026-06-17

  This study reveals that upregulation of DEGS2 and its product phytoceramide enhances prostate cancer stem-like properties through PI3K-AKT signaling. The findings identify DEGS2 as a key metabolic regulator of cancer stemness, offering new avenues for targeted intervention in castration-resistant prostate cancer.

• H 89 2HCl: Precision PKA Inhibition for Circuit-Level Neuros

  2026-06-17

  Discover how H 89 2HCl enables targeted dissection of cAMP/PKA signaling in neural circuits. By integrating selective kinase inhibition with circuit-level insights, this article explores advanced applications beyond standard PKA pathway studies.

• Epoxomicin: Precision Proteasome Inhibition for Pathway Rese

  2026-06-16

  Epoxomicin stands out as a highly selective, irreversible proteasome inhibitor for dissecting ubiquitin-proteasome pathway dynamics—enabling robust assays in protein degradation, inflammation, and disease modeling. This article unpacks advanced workflows, troubleshooting insights, and the translational impact of Epoxomicin, drawing from cutting-edge studies and best practices.

458 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page